IMVARIA

Free Access for a Limited Time! 🔓 Our published validation study on ScreenDx is now available with 50 days of free access! ScreenDx is our latest FDA-authorized tool, automatically assessing for interstitial lung findings compatible with ILD. Read here: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

How does AI actually work? What goes on behind the curtain? In this video, we break down AI in medical diagnostics, starting with Fibresolve. 🚀 🫁 Watch now to learn more! #AI #HealthcareInnovation #Fibresolve buff.ly/40ma2Rj

Just 2 days until our CEO, Joshua Reicher, joins the panel at Mayo Clinic's Beahrs Surgical Innovation Summit! Don’t miss it on November 7, 9:30 AM. See you there!

We’re thrilled to share our CEO, Joshua Reicher, will be a panelist at Mayo Clinic’s Beahrs Surgical Innovation Summit on November 7 at 9:30 AM. We’d love to see you there! For more information, check out: buff.ly/48t9rjk

“I really came to recognize the power of AI through my own experiences as a patient.” We’re excited to share our latest patient story about a journey through ILD and IPF assessment, and the role Fibresolve played in that diagnostic pathway. Watch below: buff.ly/4eH5ObK

Day 2 at #CHEST2024 is underway! We’re excited to be presenting our latest research: Expert Center External Validation of a CT-Based Deep Learning Algorithm to Predict Diagnosis of Idiopathic Pulmonary Fibrosis. Come see our poster in Area 2 to learn more!

We’re excited to be at the CHEST conference this week! Our Founder, Josh Reicher, is looking forward to continuing great conversations, learning, and building new collaborations. Hope to see you here! #CHEST2024

Thank you to everyone who joined us in Vienna for an inspiring day of collaboration and learning during our annual Member Meeting & AI/Innovation Showcase. hashtag#OSICild members are passionate in their quest to make radical progress on behalf of people living with fibrosing lung diseases, and their families and caregivers. We are so grateful for your expertise and tireless efforts. Our strength is our collective brainpower. Together, we can hashtag#CurePF! hashtag#OSICCloud Dr. Kevin Brown, Prof. David Barber, Dr. Rozsa Schlenker-Herceg, David White, Dr. Eric White, Dr. Sanaz Berahmani, Dr. Jonas Biehler, Dr. Alexandre Coimbra, Eamonn Costello, Dr. Jan De Backer, Dr. Peter George, Prof;, Georg Langs, Dr. Joshua Reicher, Tricha Shivas, Sandra Stapleton, Dr. Alexander C. Whitehead, Elizabeth Estes @NJHealth @CSLBehring @ucl @boehringerus @Imbio @Brainomix @ThisIsThirona @ebenbuild @genentech @patientMpower @FluiddaNV @contextflow_rad @imvariainc @StopSarcoidosis @vidalung

Today is ILD Day, and we're proud to stand with the global community in raising awareness about interstitial lung disease. 🫁❤️ At IMVARIA, we're committed to advancing the diagnosis of ILD with Fibresolve. Together, let's work toward a brighter future for those impacted by ILD.

📣 Exciting News! We’re thrilled to share that our CEO, Joshua Reicher, will be a guest speaker at the OSIC Member Meeting & AI/Biomarker Innovation Showcase in Vienna on Saturday, 7 September 2024 from 12:30 to 16:00 (CET). 👉 RSVP now to tune in: buff.ly/3ARiNc7

Take steps toward a cure for pulmonary fibrosis! Join the PFF Walk to raise funds and support those impacted by PF and IPF. Sign up and donate here: buff.ly/3yWHdjA

✨ We’re thrilled to announce the launch of our new Fibresolve educational webpage for individuals, families, and caregivers! 🎉 Dive in to explore how our cutting-edge solution is transforming ILD and IPF diagnosis. Learn more: buff.ly/3YSuDwA #LungHealth #Fibresolve

This is truly ground breaking news. The momentum is gathering to be able to give a definitive diagnosis of Pulmonary Fibrosis in a matter of weeks rather than years.

We're thrilled to announce the availability of Fibresolve, a groundbreaking innovation in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF)! 🫁 💙 Fibresolve is a big step forward in non-invasive assessment in a challenging disease: buff.ly/46s9lrj

🚀 Exciting News! We've just launched our new and improved website! 🌐 Visit to learn more about how we are revolutionizing pulmonary diagnostics with Fibresolve: imvaria.com #ILD #IPF #Innovation #MedicalTechnology #IMVARIA #MedTech #AI #Diagnostics

Thrilled to announce FDA Authorization of Fibresolve, the first FDA-authorized diagnostic tool in lung fibrosis (including IPF)!! And the first AI tool with FDA Breakthrough, FDA Authorization, and AMA CPT codes. Learn more here: imvaria.com/?imvaria-fibre…

Excited to be presenting more of our validation data behind Fibresolve in collaboration with @FibroGenInc and clinical experts at @uofl at the #pffsummit2023! Fibresolve was tested in data from two Phase 2 Trials... pulmonaryfibrosis.org/pff-summit

Read more about @michaelmuelly's perspectives on IMVARIA's new project with @MayoClinic in AI digital biomarkers in oncology! "Mayo Clinic will combine its large datasets for training algorithms and will utilize the IMVARIA Digital Biomarker Platform..." dotmed.com/news/story/616…

Excited to announce our new R&D collaboration with the @MayoClinic! Looking forward to expanding our AI digital biomarkers into oncology as we continue to empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease. imvaria.com/?imvaria-mayo